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Chronic thromboembolic pulmonary hypertension (CTEPH) is a form of pulmonary
hypertension caused by non-resolving thromboembolisms of the pulmonary arteries.
In Japan, in contrast to Western countries, CTEPH is more prevalent in women. A Japanese
multicenter study reported that a form of CTEPH unrelated to deep vein thrombosis is
associated with HLA-Bn5201, suggesting that this form of CTEPH may be associated with
vasculopathy. CTEPH can be cured by pulmonary endarterectomy, provided that the
thrombi are surgically accessible; thus, early diagnosis is important, and all patients with
exertional dyspnea should be evaluated for pulmonary hypertension. Ventilation/perfu-
sion scans provide an excellent non-invasive means to distinguish CTEPH from pulmonary
arterial hypertension. Similarly, computed tomographic pulmonary angiograms allow for
the detection of thrombi and evaluation of pulmonary hemodynamics in a minimally
invasive manner. Importantly, the absence of subpleural perfusion on pulmonary angio-
grams can suggest the presence of small vessel disease. Small vessel disease might be
involved in the pathogenesis of CTEPH, and its detection is essential in preventing
operative death. Although no modern therapies for pulmonary arterial hypertension have
been approved for treatment of CTEPH, a recent randomized control trial of riociguat in
patients with CTEPH demonstrated that riociguat signiﬁcantly improved 6-min walking
distance. Further investigations into treatments that target endothelial dysfunction and
hyperproliferative CTEPH cells are needed. Recently, balloon pulmonary angioplasty has
emerged as a promising treatment modality in Japan. A specialized medical team,
including at least one expert surgeon, should make decisions regarding patients' candidacy
for pulmonary endarterectomy and/or balloon pulmonary angioplasty.
& 2013 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.anese Respiratory Society. Published by Elsevier B.V. All rights reserved.
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Chronic thromboembolic pulmonary hypertension (CTEPH)
has traditionally been deﬁned as pulmonary hypertension
(PH) caused by single or recurrent pulmonary emboli arising
from deep vein thrombosis (DVT). These embolic events are
not always clinically apparent. In such cases, a silent acute
pulmonary embolism (PE) is the initiating event, and subse-
quent pulmonary vascular remodeling (small vessel disease)
causes progression to PH. Hence, modern therapies for
pulmonary arterial hypertension (PAH) may be efﬁcacious in
patients with CTEPH [1,2].
Accurate diagnosis of CTEPH is very important because
certain procedures have been shown to improve outcome.
For example, CTEPH can be cured by pulmonary endarter-
ectomy (PEA) [3–9], and balloon pulmonary angioplasty (BPA)
may improve pulmonary hemodynamics and survival in
patients with distal-type disease [10–13].
Here, we review recent progress in the diagnosis and
management of CTEPH.
2. Definition
CTEPH develops because of chronic occlusion of pulmonary
arteries by organized thrombi. It is deﬁned as a meanpulmonary arterial pressure (Ppa)≥25 mmHg and normal
pulmonary capillary wedge pressure despite anticoagulation
therapy for more than 3 months [14,15]. In patients who meet
these criteria and have segmental defects on perfusion scans,
the diagnosis of CTEPH should be conﬁrmed by chronic
embolic ﬁndings on pulmonary angiography or computed
tomographic (CT) pulmonary angiography.3. Epidemiology
In the United States, it is estimated that an acute PE occurs in
0.5 to 0.6 million individuals each year, and CTEPH develops in
approximately 0.1% to 0.5% of patients surviving the acute
phase of PE [3,16]. However, the incidence of CTEPH may be
higher; a recent study showed that CTEPH occurs in 3.8%
of patients with a history of acute PE [17]. Another study
revealed that the cumulative incidence of CTEPH is 0.57% in
all patients with PE and 1.5% in patients with unprovoked
PE [18]. Thus, physicians should be aware of the risk of
progression to CTEPH when treating patients with acute PE. In
Japan, the Respiratory Failure Research Group from the Ministry
of Health, Labor andWelfare (MHLW) established criteria for the
diagnosis of CTEPH during a nationwide survey in 1997. The
number of patients with CTEPH was estimated to be 450 (95%
r e s p i r a t o r y i n v e s t i g a t i o n 5 1 ( 2 0 1 3 ) 1 3 4 – 1 4 6136conﬁdence interval, 360–530) [19], which designated it as a
speciﬁed rare and intractable disease. The MHLW has since
conducted annual epidemiological surveys of CTEPH. In 2010,
1288 patients with CTEPH were registered as having this
speciﬁed rare and intractable disease [20].4. Etiology and characteristics of Japanese
CTEPH
The pathogenic mechanisms that cause CTEPH are still
uncertain. CTEPH is considered as a chronic condition occur-
ring in patients with a history of acute PE caused by DVT.
However, up to 40% of patients with CTEPH have not had
clinically apparent acute embolic episodes [21].
CTEPH results from obstruction of more than 40% of the
pulmonary vascular bed by unresolved thromboemboli [22].
Thrombophilia due to mutations in protein C, protein S,
antithrombin, prothrombin, or factor V has not been signiﬁ-
cantly associated with CTEPH. Factors that have been linked
to CTEPH include anti-cardiolipin antibodies, which are found
in 10% to 20% of patients, and elevated factor VIII [23,24].
Several additional risk factors have been associated with
CTEPH, including chronic inﬂammatory disorders, myelopro-
liferative syndromes, and splenectomy [25]. The association
of CTEPH with these conditions suggests that chronic inﬂam-
matory processes are involved in its pathogenesis.
Patients with CTEPH may remain asymptomatic for months
or years (“honeymoon period”) regardless of whether or not
they have a history of acute embolic episodes. The pathological
mechanisms that occur during this asymptomatic period are
unknown. It is possible that recurrent thromboembolism and
in situ thrombosis are involved in the progression to sympto-
matic PH. However, several investigators have suggested that
PH results from pulmonary vascular remodeling (small vessel
disease) that occur secondary to the initial PE event. If CTEPH is
indeed a small vessel disease, it may develop in a manner
similar to PAH [1,2,26].Table 1 – .
Parameters J
Number of patients (n) 5
Gender, % male 2
Age, y, median [Q1; Q3] 6
World Health Organization classa, % I/II/III/IV 5
6-min walk distance, m, median [Q1; Q3] 3
History of deep vein thrombosisa, % 5
History of acute pulmonary embolisma, % 3
Coagulopathiesa, % 1
Cancera, % 6
Mean pulmonary arterial pressure, mmHg, median [Q1; Q3] 3
Pulmonary vascular resistance, dyn s cm−5, median [Q1; Q3] 6
Pulmonary endarterectomy, % 1
Inferior vena cava filter, % 2
Modern pulmonary arterial hypertension therapy, % 5
Values are expressed as medians with ﬁrst and third quartiles [Q1; Q3
(n¼138).
NA, not assessed.
a p value obtained from the chi-square test.Analysis of a subset of 519 patients among the 1288 patients
in the MHLW CTEPH registry in 2011 revealed that female
patients outnumbered male patients (2.6:1), and the mean age
was 64713 years. Interestingly, while no gender difference
was observed in younger patients, the female-to-male ratio
increased in patients older than 40 years of age [27].
A comparison of important clinical characteristics
between patients in the Japanese MHLW registry and those
in the international registry is shown in Table 1 [28]. Japanese
patients were predominantly female, had better World
Health Organization (WHO) functional status, mild hemody-
namic impairment, fewer incidents of acute PE, and fewer
coagulopathies. Signiﬁcantly fewer patients in the Japanese
registry underwent PEA, which may be related to the fact that
patients who improved after surgery were excluded from
the registry until 2009. Nonetheless, fewer patients in the
Japanese registry underwent surgical treatment. Similar
to patients in the international registry, however, half of
the Japanese patients underwent operations at Chiba Uni-
versity Hospital, one of the PEA referral centers in Japan [29].
Japanese patients were more likely to have an inferior
vena cava ﬁlter, even in medically treated cases. In addition,
Japanese patients were more likely to be prescribed modern
PAH therapies, even in surgically treated cases [27].
Shigeta et al. reported a Japanese series in which female
patients with CTEPH were more likely to be elderly, have
fewer occurrences of DVT or acute embolic episodes, and
have different clinical characteristics than male patients with
CTEPH [30].
Tanabe et al. found a signiﬁcantly higher frequency of
HLA-Bn5201 in Japanese patients with CTEPH (40%) than in
normal controls (24%) or in patients with acute PE (10%), and
HLA-Bn5201—positive patients were predominantly female
(83%) [24]. The frequency of HLA-Bn5201 in patients with
CTEPH was similar to that reported in patients with Takayasu
arteritis (41.3%), a chronic vasculitis involving the aorta and
its major branches as well as the coronary and pulmonary
arteries. Multicenter Japanese studies have revealed a strongapanese registry International registry p value
19 679 NA
8.1 50.1 o0.0001
7 [53;75] 63 [51;72] NA
.2/41.9/47.7/5.2 0.7/17.8/68.6/12.8 o0.0001





8 [33;46] 47 [38;55] NA




] or percentages. Data are from new cases in the Japanese Registry
r e s p i r a t o r y i n v e s t i g a t i o n 5 1 ( 2 0 1 3 ) 1 3 4 – 1 4 6 137association of IKBLnp03 (odds ratio, 2.33; 95% conﬁdence
interval, 1.49–3.66; p¼0.00017; pc¼0.033) and Bn5201 (odds
ratio, 2.47; 95% CI, 1.56–3.90; p¼0.000086; pc¼0.016) with DVT-
negative CTEPH [31]. IKBLnp03 is a polymorphism in the
promoter region of the gene coding for nuclear factor κB
inhibitor-like protein (IKBL-p allele), and it has been asso-
ciated with Takayasu arteritis [32]. Hence, inﬂammatory
processes may be involved in the pathogenesis of DVT-
negative CTEPH in Japanese populations. It should be noted
that Takayasu arteritis was differentiated from CTEPH in this
study by CT angiography and by the absence of macroscopic
ﬁndings during surgery. We have observed thrombus growth
into the proximal side of the pulmonary artery in 3 HLA-
Bn5201-positive patients whose C-reactive protein levels were
o0.3 mg/dL. The results of one autopsy showed diffuse
inﬂammatory cell inﬁltrates in the media of the large elastic
pulmonary arteries to which thrombi were attached. Those
ﬁndings mimicked Takayasu arteritis but were differentiated
from this entity based on the lack of adventitial lesions. It is
possible that more cases of undiagnosed pulmonary arteritis
secondary to thrombi have occurred in HLA-Bn5201-positive
patients with CTEPH [24].
4.1. Clinical presentations
Progressive exertional dyspnea and exercise intolerance are
common in patients with CTEPH, whether or not they have a
history of clinically relevant acute PE. A “honeymoon period”
between the acute episode and the diagnosis of CTEPH is
common and may last from months to years [2,16,22].
In patients who do not have a known history of acute PE,
progressive exertional dyspnea and fatigue appear to be
caused by elevated Ppa and decreased maximal cardiac out-
put, similar to patients with PAH. As the disease progresses,
patients develop exertional chest pain, syncope, and lower
extremity edema, which are indicative of decreased cardiac
output at rest and right heart failure.
In a study of patients with inoperable CTEPH, patients
with a mean Ppa440 mmHg had a poor prognosis (5-year
survival, ~30%) but those with a mean Ppao30 mmHg did
not [33]. Hence, precise evaluation and surgical intervention,
when appropriate, are essential to survival.
Physical ﬁndings of CTEPH are often subtle but may
include a prominent pulmonary component of S2 and a
systolic murmur reﬂecting tricuspid regurgitation. Signs of
right heart failure (distended neck veins, edema, ascites, and
acrocyanosis) occur later in the course of the disease.
Approximately 30% of patients have a bruit somewhere in
the lung ﬁelds. These ﬂow murmurs originate from turbulent
blood ﬂow through partially occluded vessels or through
recanalized thrombi [2].
4.2. Diagnostic strategy
PH, including CTEPH, should be suspected in all patients with
unexplained dyspnea [14,15]. Suspicion should be even
higher in patients who have had a PE and/or DVT. The ﬁrst
objective ﬁnding in early CTEPH may be desaturation during
exercise [3]. Echocardiography is widely used as an initial test
for detecting PH and excluding left heart disease and shunt.Screening echocardiography, performed 6 weeks after the
diagnosis of acute PE, can identify patients with persistent PH
and may be of value in planning follow-up care [34]. Chest
roentgenography may be normal in early CTEPH and is thus
not diagnostic, although several abnormalities may occur in
later stages of disease [3]. Electrocardiography is also non-
diagnostic; however, certain ﬁndings are associated with PH,
including right ventricular hypertrophy or strain with right
axis deviation, complete or incomplete right bundle branch
block, and nonspeciﬁc ST–T changes in leads V1 to V3. PaO2
may also be normal, although the alveolar–arterial oxygen
tension gradient is typically widened.
Ventilation/perfusion (V/Q) scans are excellent noninva-
sive tests with which to distinguish CTEPH from PAH [14,15],
while CT angiography is useful for differentiating CTEPH from
arteritis, tumors, and congenital anomalies of the pulmonary
arteries [15,21,35]. Pulmonary angiography is still considered
the gold standard for evaluation of CTEPH. Right heart
catheterization is required to conﬁrm precapillary PH (mean
Ppa≥25 mmHg and pulmonary capillary wedge pressure
≤15 mmHg) after patients have been adequately anticoagu-
lated for more than 3 months [14,15].5. Imaging
5.1. Chest roentgenography
In patients with CTEPH, chest roentgenography may appear
normal and demonstrate clear lung ﬁelds, but close exam-
ination may reveal areas of hyperperfusion or hypoperfusion
with enlargement or asymmetry of the central pulmonary
arteries. Right atrial and right ventricular enlargement may
occur in PH and will appear on lateral CT views as obliteration
of the retrosternal space by the cardiac shadow [3]. Satoh
et al. reported that an avascular area or marked dilatation of
the right descending pulmonary artery, together with pleuri-
tic changes, suggests the presence of CTEPH [36].
5.2. V/Q scans and single photon emission computed
tomography
In patients with unexplained PH, a V/Q scan is recommended to
exclude CTEPH [2,21,22,25]. The presence of either normal or
mottled perfusion scans can suggest PAH, while even one
unmatched perfusion defect suggests CTEPH (Fig. 1). Matched
perfusion defects and elevated ventilation-to-perfusion defects
suggest PH due to lung disease and/or hypoxemia. In a study of
227 patients that compared detection of CTEPH by V/Q scan with
detection by multi-slice computed tomographic pulmonary
angiography (CTPA), V/Q scans demonstrated a sensitivity of
96%–97.4% and a speciﬁcity of 90%–95% and CTPA demonstrated
a sensitivity of 51% and a speciﬁcity of 99% [37]. Although V/Q
scans demonstrated a higher sensitivity in detection of CTEPH
(Fig. 1), V/Q ﬁndings have been shown to understate the severity
of angiographic ﬁndings and do not correlate with pulmonary
vascular resistance (PVR) or mean Ppa [38].
A recent pilot study comparing single-photon emission
computed tomography (SPECT) perfusion scans with CTPA
showed that SPECT is more sensitive than CTPA in identifying
r e s p i r a t o r y i n v e s t i g a t i o n 5 1 ( 2 0 1 3 ) 1 3 4 – 1 4 6138obstructed segments [39] (Fig. 2a and b). The investigators
suggest that this increased sensitivity might be important not
only during initial evaluations but also during postsurgical
follow-up care [39].
5.3. CTPA
CTPA is often the ﬁrst choice for imaging in patients who have
had a recent acute embolic episode. CT angiography is also
indicated when a V/Q scan is indeterminate or shows perfusion
defects. Recently, 64- or 320-detector row CTPA has been shown
to be an accurate and reliable noninvasive alternative to
pulmonary angiography in evaluating patients with CTEPH.
The sensitivity and speciﬁcity of CTPA in detecting thromboem-
bolic ﬁndings were 97.0%–98.3% and 94.8%–97.1% at the main/
lobar level, respectively, and 85.8%–94.1% and 92.9%–94.6% at
the segmental level, respectively [40,41]. Three-dimensional CT
angiography reveals chronic embolic ﬁndings consistent with
those in pulmonary angiography (Fig. 3); however, poor correla-
tion between the CT-derived obstruction index and PVR has
been reported [42]. Pulmonary vascular remodeling may result
in a disproportionately elevated PVR compared with that
produced by proximal thrombi. Recently, the development of
electrocardiography-gated CTPA has allowed for the simulta-
neous evaluation of thrombi location and right ventricular
function. Sugiura et al. reported good correlation between
bowing of the interventricular septum (expressed as curvature)
and systolic Ppa (r¼−0.79, po0.001) and mean Ppa (r¼−0.86,
po0.001) [41] (Fig. 4). Liu et al. reported that the Cobb angle (the
angle between the interventricular septum and the line
between the sternal midpoint and thoracic vertebral spinous
process, measured during diastole) on transverse images is a
reliable tool for estimating PVR [42].
CTPA is also used to differentiate CTEPH from other
pulmonary vascular diseases in patients with perfusion
defects. Unilateral obstruction on perfusion scans is rare in
CTEPH but suggests the presence of other diseases, such as
sarcoma of the pulmonary artery (Fig. 5c), Takayasu arteritis
(Fig. 5d), cancer, or mediastinal ﬁbrosis [15,21,35]. In addition,
3-dimensional CTPA is used to differentiate CTEPH from
congenital anomalies of the pulmonary arteries [43]. High-
resolution CT of the lung shows a diagnostic pattern of
mosaic attenuation (mixed hypoperfused and hyperperfused
areas) in CTEPH, independent of the presence of contrast
media (Fig. 2d) [35].
Dual-energy CTPA allows for evaluation of lung perfusion
and thrombus location. Simultaneous acquisition of data sets
at 80 and 140 kV can be used to visualize iodine distribution
maps (lung perfusion blood volume images) in the pulmonary
parenchyma, which reﬂect lung perfusion. Imaging of lung
perfusion blood volume by dual-energy CT has been reported
to be comparable to SPECT perfusion scans in establishing a
diagnosis of CTEPH [44].
5.4. Magnetic resonance imaging
Magnetic resonance (MR) imaging may also provide a clear
diagnosis of CTEPH [33], but a recent report suggested that it
is less effective than multidetector CTPA in assessing the
pulmonary arteries of patients with CTEPH [45]. However,contrast-enhanced MR angiography may be useful in discri-
minating central thromboembolic lesions from tumors; with
contrast-enhanced MR, the latter are enhanced with gadoli-
nium, whereas the former are not [2]. Moreover, MR imaging
is the gold standard for quantifying right ventricular function
and dimensions in patients with PAH or CTEPH [35]. This is
important because Reesink et al. reported that after PEA,
changes in total PVR correlate with changes in right ventri-
cular ejection fraction, right ventricular mass, and leftward
ventricular septal bowing [46].5.5. Pulmonary angiography
Pulmonary angiography is the gold standard for diagnosing
CTEPH and assessing operability [14,15,21]. Five distinct
angiographic ﬁndings correlate with the presence of orga-
nized thromboemboli: pouch defects, webs or bands, intimal
irregularities, abrupt narrowing, and complete obstruction
[47]. Pulmonary angiography allows for visualization of prox-
imal and distal thromboembolic ﬁndings in the elastic
pulmonary arteries. It also helps to determine if thromboem-
boli are surgically accessible by providing an assessment of
capillary perfusion (Fig. 6) [48]. Pulmonary angiography can
be performed safely in patients with severe CTEPH and is
often performed in conjunction with a diagnostic right heart
catheterization [49]. Selective nonionic contrast injections
into the right and left main pulmonary arteries should be
performed on a biplane digital subtraction system. It should
be noted that, unlike CTPA, pulmonary angiography cannot
fully assess the pulmonary trunk [45].6. Classic therapy
Patients with CTEPH, whether treated medically or with PEA,
must receive lifelong anticoagulant therapy to avoid a recur-
rence of venous thromboembolism and to prevent progres-
sion of thrombus growth within the pulmonary arteries
[14,15,21]. Warfarin is the most commonly used anticoagu-
lant and is generally administered to achieve a prothrombin
time/international normalized ratio of 2 to 3 (1.5 to 2.5
according to Japanese guidelines) [14,15]. Patients who
experienced an acute embolic episode show rapid disease
progression. When D-dimer levels are high during disease
progression, thrombolytic therapy may improve outcome [15].
Finally, although there is no conclusive evidence regarding the
utility of oxygen therapy in patients with CTEPH, it is believed
to improve both quality of life and prognosis [15].7. PEA
PEA, a standard surgical procedure for removal of surgically
accessible central thrombi, is performed worldwide, usually
at expert centers [3–9]. PEA offers early and signiﬁcant
decreases in both mean Ppa and PVR and later improvements
in gas exchange [50].
Fig. 1 – Diagnostic approach to pulmonary hypertension of unknown etiology.
Fig. 2 – Comparison of SPECT, pulmonary angiography, and computed tomography (a) SPECT perfusion scan, (b) colored
image of SPECT perfusion scan, (c) pulmonary angiography and (d) lung window on CTPA. Mosaic perfusion patterns on
CTPA are consistent with hyperperfused areas and perfusion defects on SPECT. SPECT, single-photon emission computed
tomography; CTPA, computed tomographic pulmonary angiography.
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The selection criteria for PEA include (1) mean Ppa430mmHg
(resulting in a calculated PVR of 4300 dyn s cm−5) even afteroral anticoagulant therapy for46 months, (2) WHO functional
class ≥2, (3) thrombi that are accessible to current surgical
techniques (i.e., located in the main, lobar, or segmental
arteries), and (4) absence of severe associated disease [15,51].
Fig. 3 – Comparison of embolic findings between pulmonary angiography and 3-dimensional CTPA. (a) Pulmonary
angiography and (b) three-dimensional CTPA. Chronic embolic findings similar to those in pulmonary angiography are
observed. CTPA, computed tomographic pulmonary angiography.
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daily activity, surgery should be considered even in those with
mild resting PH and exercise-induced PH [3,26].7.2. Surgical technique
The PEA procedure developed at the University of Califor-
nia, San Diego is performed through a median sternotomy
and requires intermittent deep hypothermic circulatory
arrest [3,51]. This surgical procedure has been described
in detail elsewhere [3,51]. Brieﬂy, PEA is performed with
intermittent circulatory arrest to avoid bleeding from
systemic-to-pulmonary collateral circulation, and deep
hypothermia (20 1C) is induced to prevent brain damage.
It is important to ﬁnd the correct dissecting plane during
endarterectomy, because the plane is followed all the way
to the lobar, segmental, or subsegmental arteries of
each lobe.
An inferior vena cava ﬁlter should be considered before
surgery to prevent recurrent emboli within the perioperative
period, particularly in patients with a history of DVT [3,26,51].
Cardiovascular risk should be assessed preoperatively by
coronary angiography or CT coronary angiography, and
coronary artery bypass surgery, if necessary, can be per-
formed without risk [38,48].7.3. Short-term results
Thistlethwaite et al. reported an overall mortality of 4.7% in 1100
consecutive patients who underwent PEA [51]. Patients with a
postoperative PVR 4500 dyn s cm−5 had signiﬁcantly higher
mortality (5.7%) compared with those with a postoperative PVR
o500 dyn s cm−5 (1.2%). The investigators classiﬁed intraopera-
tive thromboembolic disease into 4 types: type 1, fresh thrombus
in the main/lobar pulmonary arteries (37.7%) (Fig. 6b); type 2,
intimal thickening and ﬁbrosis proximal to the segmental
arteries (42.6%); type 3, disease within distal segmental arteries
only (17.5%); and type 4, distal arteriolar vasculopathy without
visible thromboembolic disease (2.2%). Patients with distal
thromboembolic disease type 3 or type 4 had higher periopera-
tive mortality (6.3% and 16.7%, respectively) than patients with
type 1 or type 2 disease (3.9% and 4.7%, respectively) [51]. Results
from a prospective international registry revealed that median
PVR decreased from 698 dyn s cm−5 before PEA to 235 dyn s cm−5
after PEA, and in-hospital mortality was 4.4% [6]. In Japan, similar
levels of operative mortality were reported by Ando et al. (8.3%
when undergoing elective PEA) [7], Ogino et al. (8.0%) [8], and
Ishida et al. (initially 14%, but more recently reduced to 7.5%) [9].
7.4. Long-term results
The University of California, San Diego group achieved a
6-year survival rate of 75% in 308 patients who underwent
Fig. 4 – Calculation of interventricular septal curvature and its correlation with pulmonary hemodynamics. (a) The
interventricular septal curvature was measured on the short-axis image plane at the midventricular level (at least one
papillary muscle visible). At this level, the cine image with the most deformation of the septum (in this case, at 35% of the
R–R interval) was used for quantification. (b) Three points at the anterior, middle, and posterior positions of the
interventricular septum were marked, and the X and Y coordinates were recorded. (c) A circle passing through the 3 points
on the septum was used to calculate the radius of curvature of the septum. A rightward (physiologic) curvature was denoted
as a positive value and a leftward curvature as a negative value. (Window/Center settings were 600/150 HU.) (d) Correlation
between interventricular septal curvature obtained by 320-slice computed tomography and sPAP based on right heart
catheterization. The scatter plot shows the relationship between interventricular septal curvature and sPAP (r¼−0.79,
po0.001). (e) Correlation between interventricular septal curvature obtained by 320-slice computed tomography and mPAP
by right heart catheterization. The scatter plot shows the relationship between interventricular septal curvature and mPAP
(r¼−0.86, po0.001). Reproduced from Sugiura et al. [41] with the authors’ permission. sPAP, systolic pulmonary arterial
pressure; mPAP, mean pulmonary arterial pressure.
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et al. reported a 5-year survival rate of 84% in 157 patients
who underwent PEA between 1994 and 2006 [5]. In Japan,
Ishida et al. reported that freedom from disease-speciﬁc
death was 84% and 82% at 5 and 10 years, respectively
[9].
7.5. Risk factors for surgery
Several reports have demonstrated that high preoperative
PVR is a signiﬁcant prognostic factor for postsurgical compli-
cations [1,2,6,21]. One international registry showed that the
mortality rate was 2.8% in patients with PVRs between 400
and 800 dyn s cm−5, 5.8% in patients with PVRs between
800 and 1200 dyn s cm−5, and 10.6% in patients with PVRs41200 dyn s cm−5 [6]. One explanation for this is that patients
with PVRs that are disproportionate to the amount of visible
central lesion obstruction are likely to have distal thrombi
and severe pulmonary vascular remodeling, which results in
poor outcome after PEA [1,2]. Kim et al. used pulmonary
arterial occlusion waveform analysis to determine that
upstream resistance was inversely correlated to both post-
operative total pulmonary vascular index and mean Ppa.
Further, all non-survivors had upstream resistance o60%, indi-
cating peripheral-type disease [52]. Tanabe et al. recently used
the capillary phase in pulmonary angiography to focus on
subpleural perfusion and found that the absence of subpleural
perfusion in any segment, coupled with high PVR, might be
related to small vessel disease and results in poor outcome after
surgery [48].
Fig. 5 – Comparison of computed tomographic pulmonary angiography in patents with unilateral perfusion defect on
perfusion scan. (a and b) Chronic thromboembolic pulmonary hypertension. The edge of the thrombus is dull and smooth.
(c) Sarcoma of the pulmonary artery. Thrombus-like material occupies the right pulmonary artery and looks like an invasive
and extended left pulmonary artery. A large mass occupies the right main pulmonary artery and extends into the left.
(d) Isolated involvement of pulmonary arteries by Takayasu arteritis. Total stenosis of the right pulmonary artery by fibrous
material, increased wall thickness of the left pulmonary artery, and normal distal arteries are observed.
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The progression of CTEPH may be caused by small vessel
disease, similar to PAH, but no medications for PAH have
been approved for the treatment of CTEPH [1,2]. However,
medications for PAH been used off-label in patients with
CTEPH who have inoperable disease or patients with persis-
tent PH after PEA and have been used as therapeutic bridges
before PEA [26]. According to the international registry, more
than one-third of patients with CTEPH were treated medi-
cally. Of those, half received modern PAH therapies such as
phophodiesterase-5 inhibitors and endothelin receptor anta-
gonists [28]. Similarly, a Japanese series showed that more than
half of patients with CTEPH were treated with the modern PAH
medications beraprost, bosentan, or sildenaﬁl [27].8.1. Endothelin receptor antagonists
In a randomized controlled trial (RCT) of patients with
inoperable disease or persistent PH after surgery, treatment
with bosentan led to a signiﬁcant improvement in PVR
(−24.1% of baseline) but did not signiﬁcantly improve 6-min
walk distance (6MD) [53]. In a recent meta-analysis of 11
studies (totaling 269 patients), bosentan was associated with
improved pulmonary hemodynamics and exercise capacity
[54]. In an uncontrolled study of several types of PH, ambri-
sentan led to a modest increase in 6MD (mean, 17 m) in
patients with CTEPH [55].8.2. Phosphodiesterase-5 inhibitors
Reichenberger et al. showed that sildenaﬁl improved PVR and
6MD in an open-label study of 104 patients with inoperable
CTEPH [56]. In a small double-blind RCT of patients with
inoperable CTEPH, Suntharalingam et al. reported that silde-
naﬁl did not signiﬁcantly improve 6MD relative to placebo but
signiﬁcantly improved several secondary endpoints at both 3
months (PVR and WHO class) and 12 months (6MD, PVR, WHO
class) [57]. They further reported that the change in PVR after
12 months of treatment with sildenaﬁl correlated with the
change in PVR during vasoreactivity testing with sildenaﬁl.8.3. Prostanoids
Olchewski et al. reported the results of a RCT in which
inhaled iloprost was tested in 203 patients with PH, including
57 patients with CTEPH. Iloprost improved exercise capacity
and pulmonary hemodynamics compared with placebo, but
the beneﬁcial effect was less prominent in patients with
CTEPH than in patients with PAH [58]. In an uncontrolled
study of 28 patients with inoperable CTEPH, subcutaneous
treprostinil therapy signiﬁcantly improved PVR. Furthermore,
5-year survival in patients treated with treprostinil was
signiﬁcantly better than in a historical control group (53%
vs. 16%) [59]. In a retrospective study of 27 patients with
inoperable CTEPH, epoprostenol improved mean Ppa, total
PVR, 6MD, and New York Heart Association class [60]. In an
uncontrolled study in Japan, Ono et al. reported that oral
beraprost improved New York Heart Association class in 10
Fig. 7 – Selective pulmonary angiograms before, during, and after BPA. (a) Pulmonary angiogram before BPA. Mean Ppa was
38 mmHg, and PVR was 632 dyn s cm−5. (b) Pulmonary angiogram during balloon inflation. (c) Pulmonary angiogram after
BPA. After BPA of 7 vessels, mean Ppa decreased to 21 mmHg and PVR decreased to 312 dyn s cm−5. Pictures of pulmonary
angiograms were provided by Professor Toru Satoh and Dr. Takumi Inami with permission. BPA, balloon pulmonary
angioplasty; Ppa, pulmonary arterial pressure.
Fig. 6 – Pulmonary angiograms before and after PEA, with thromboembolic material removed from both pulmonary arteries.
(a) Pulmonary angiograms before PEA. Mean Ppa was 41 mmHg, and PVR was 823 dyn s cm−5. (b) Thromboembolic material,
which contained fresh and organized thrombus-like pulmonary arterial casts, removed from both pulmonary arteries
(type 1). (c) Pulmonary angiograms after PEA. Perfusion of both descending pulmonary arteries was significantly improved,
mean Ppa decreased from 41 to 13 mmHg, and PVR decreased from 823 to 233 dyn s cm−5. PEA, pulmonary endarterectomy;
Ppa, pulmonary arterial pressure; PVR, pulmonary vascular resistance.
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resistance from 1876 to 1578 Wood units (po0.05). Sixteen
patients died of cardiopulmonary causes in the group receiv-
ing conventional therapy, while only 3 patients died of
cardiopulmonary causes in the group receiving beraprost [61].9. Recommendation for modern PAH therapy
The clinical efﬁcacy of modern PAH therapy in CTEPH
remains to be demonstrated by an RCT. However, Condliffe
et al. recently reported improved survival in patients treated
with endothelin receptor antagonists and phophodiesterase-
5 inhibitors [62], and Nishimura et al. reported improvedsurvival in patients treated with bosentan and sildenaﬁl [29].
Recently, an international RCT showed that patients with
CTEPH treated with soluble guanyl cyclase (riociguat) had a
statistically signiﬁcant improvement in 6MD and PVR [63,64].
Jensen et al. have suggested that modern PAH therapy has
minimal effect on pre-PEA pulmonary hemodynamics and no
effect on post-PEA outcomes/hemodynamics [65]. The guide-
lines recommend that patients with CTEPH should ﬁrst be
assessed for PEA eligibility at an expert center. Next, their
eligibility for clinical studies should be evaluated. In the
remaining cases, patients can be treated with off-label mod-
ern PAH therapy over a limited period, such as 6 months, and
then reevaluated to determine if continuation of therapy is
justiﬁed [66].
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Many patients with CTEPH have disease that is not amenable
to surgery, and other interventions are required. Feinstein
et al. performed BPA in 18 patients with CTEPH. Each patient
underwent an average of 2.6 procedures (range, 1 to 5) and 6
dilations (range, 1 to 12). Approximately 36 months after BPA,
the average WHO class improved from 3.3 to 1.8 (po0.001),
6MD increased from 209 to 497 yards (po0.0001), and the
mean Ppa decreased from 43.0712.1 to 33.7710.2 mmHg.
However, 11 patients developed reperfusion pulmonary
edema, 3 required mechanical ventilation, and 1 died [10].
Recently, Japanese investigators improved upon the tradi-
tional BPA technique by using smaller-sized balloons and
dilating fewer lobes per procedure under the application of
modern PAH therapies and noninvasive positive pressure
ventilation. These modiﬁcations resulted in improved efﬁ-
cacy and fewer severe complications due to reperfusion
injury [11–13] (Fig. 7). Of note, it is possible to perform BPA
multiple times in patients who have unresolved PH after PEA.
Although the long-term survival beneﬁt of BPA remains
uncertain, improved hemodynamics could result in improved
survival. It remains unclear, however, if BPA improves gas
exchange, and the necessity of modern PAH therapy before
and/or after BPA remains controversial.10.1. Current practical treatment
Recent surgical techniques have decreased the mortality rate
during PEA and made it possible to perform endarterectomy in
patients with distal-type thrombi (type 3). However, modern
PAH therapy and BPA are emerging as alternative treatments
for patients with surgically inaccessible disease and in patients
who refuse PEA. BPA could be a high-risk procedure in patients
with high PVR (which indicates severe pulmonary vascular
remodeling), in contrast to patients with mild to moderate
PVR (which indicates distal thrombi). However, BPA in combi-
nation with modern PAH therapy might be safe and practical in
severe cases. We suggest that a specialized medical team,
including at least one expert surgeon, should make decisions
regarding the patient’s candidacy for PEA and/or BPA.10.2. Future treatment
Maruoka et al. and Sakao et al. reported that organized
thrombotic tissue in CTEPH is composed of myoﬁbroblast-
like cells, characterized as hyperproliferative and anchorage
independent. Myoﬁbroblast-like cells promote endothelial
cell transition to other mesenchymal phenotypes and/or
induce endothelial cell dysfunction [67,68]. Ogawa et al.
reported that inhibition of mTOR attenuates reduced
platelet-derived growth factor-stimulated cell proliferation
in CTEPH [69]. Both groups propose that rapamycin may have
therapeutic beneﬁt in CTEPH [67,69]. Imatinib and other
antiproliferative therapies are being evaluated in PAH [70],
but the value of systemic or local antiproliferative therapy in
patients with CTEPH requires further investigation.11. Conclusion
Modern PAH therapies may have beneﬁcial effects in CTEPH,
and clinical studies investigating new drugs for patients with
inoperable CTEPH are under way. Recent advances in BPA are
likely to change the CTEPH treatment algorithm. It is impor-
tant to diagnose CTEPH early to determine surgical candidacy
and reduce surgical risk. To prevent the progression of
CTEPH, the mechanisms underlying the chronicity of PE
should be elucidated, as well as the role of endothelial
dysfunction, inﬂammation, and hyperproliferative cells.Conflicts of interest
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